

**SENATE
STATE OF MINNESOTA
NINETIETH SESSION**

S.F. No. 1221

(SENATE AUTHORS: FISCHBACH)

DATE
02/20/2017

D-PG

OFFICIAL STATUS
Introduction and first reading
Referred to Health and Human Services Finance and Policy

1.1 A bill for an act
1.2 relating to human services; allowing the early periodic screening, diagnosis, and
1.3 treatment program to cover stiripentol; amending Minnesota Statutes 2016, section
1.4 256B.0625, subdivision 64.

1.5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

1.6 Section 1. Minnesota Statutes 2016, section 256B.0625, subdivision 64, is amended to
1.7 read:

1.8 Subd. 64. **Investigational drugs, biological products, and devices.** Medical assistance
1.9 and the early periodic screening, diagnosis, and treatment (EPSDT) program do not cover
1.10 costs incidental to, associated with, or resulting from the use of investigational drugs,
1.11 biological products, or devices as defined in section 151.375, except that stiripentol may
1.12 be covered by the EPSDT program for an eligible enrollee with a documented diagnosis of
1.13 Dravet syndrome, for whom all other available covered prescription medications for Dravet
1.14 syndrome have been exhausted. Stiripentol may only be covered if the United States Food
1.15 and Drug Administration has approved the treating physician's individual patient
1.16 investigational new drug application (IND) for the use of stiripentol for treatment or
1.17 emergency use.